What Is the New Covid Variant BA.3.2 and Should You Be Worried?

Scientists first identified the BA.3.2 COVID variant in a respiratory sample in South Africa in November 2024. The new COVID variant has since spread to dozens of countries across multiple continents. The WHO designated BA.3.2 a Variant Under Monitoring on December 5, 2025. Here is what you need to know.

What is the BA.3.2 COVID Variant?

BA.3.2 is a heavily mutated Omicron subvariant of SARS-CoV-2, descended from an ancestral BA.3 lineage that had not circulated since early 2022. Much like BA.2.86 appeared suddenly in 2023, BA.3.2 is a long-branch descendant, an evolutionary jump from a strain scientists had largely stopped tracking. CDC researchers describe it as genetically distinct from the JN.1 lineages dominating global circulation since January 2024.

How Mutated is this New COVID-19 Strain?

BA.3.2 carries approximately 70 to 75 genetic changes in its spike protein compared to the JN.1 lineage. This level of mutation is far greater than earlier Omicron subvariants, raising concern among researchers tracking SARS-CoV-2 variant evolution globally.

How Far Has the COVID Variant Spread?

As of February 11, 2026, BA.3.2 had been reported in 23 countries. In the US, it was detected in clinical samples from five patients and 132 wastewater samples from 25 states. Weekly detections reached about 30 percent of sequences in Denmark, Germany, and the Netherlands between November 2025 and January 2026.

Can BA.3.2 Escape Current Vaccine Protection?

Lab studies show BA.3.2 evades antibodies activated by COVID vaccines due to spike protein mutations. The 2025-2026 LP.8.1-adapted mRNA vaccine showed the lowest neutralization against BA.3.2 among seven variants tested. The WHO states approved vaccines are still expected to protect against severe disease.

Is BA.3.2 Causing More Severe Illness?

Reported cases have not been more severe than other COVID-19 infections. The variant was detected in hospitalized patients in three US states, including two older adults with existing health conditions. The WHO currently places BA.3.2 at a low overall risk level.

What are BA.3.2's Subvariants and Which is More Concerning?

BA.3.2 has split into two main branches: BA.3.2.1, assigned the Pango ID RD, and BA.3.2.2, assigned RE. The RE.1 sublineage is currently drawing the most attention, with surveillance data showing its circulation across Western Australia, New Zealand, and parts of the Netherlands. 

As per the WHO TAG-VE risk evaluation, high prevalence of BA.3.2 has been reported in areas such as Western Australia. However, as per New Zealand's PHF Science genomic report, RE.1.1 has not yet shown a significant growth advantage over other circulating lineages.

What are Health Authorities Doing to Track this SARS-CoV-2 Variant?

The CDC is using genomic surveillance to monitor BA.3.2 across the United States and internationally. WHO's TAG-CO-VAC continues assessing its impact on vaccine performance. Staying current on COVID-19 vaccinations remains the most effective individual response.

(With inputs from yMedia)